GenSpera Announces US Patent for Methods and Compositions for the Detection, Imaging and Treatment of Cancer

SAN ANTONIO, July 30, 2014 /PRNewswire via COMTEX/ GenSpera, Inc. (OTCQB: GNSZ), a leader in developing prodrug therapeutics for the treatment of cancer, announces the issuance of a United States patent entitled Methods and compositions for the detection of cancer . The patent US 8,772,226 B2 was issued July 8, 2014. The patent contains composition claims for thapsigargin-containing prodrugs that can be radiolabelled and then activated by the enzymes Prostate Specific Membrane Antigen (PSMA), Prostate Specific Antigen (PSA) or Human Glandular Kallikrein 2 (hK2). The patent also claims methods of using such radiolabelled prodrugs for the detection, imaging and treatment of cancers in humans. The co-inventors on the patent include Drs. Samuel Denmeade, John Isaacs and Soren Brogger Christensen who are all members of GenSpera s Scientific Advisory Board. As we evaluate G-202 further in the liver cancer and glioblastoma Phase II clinical trials it is clear that the technology described in
http://bit.ly/1qLrvxA